Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547233 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
A Phase 3 study of Actinic Keratosis, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 437
- Enrollment target
- 1
- Study location
NCT02547233: Completed Phase 3 study of Actinic Keratosis, sponsored by LEO Pharma.
NCT02547233 is a Phase 3 study of Actinic Keratosis that has completed, run by LEO Pharma. The registered enrollment target is 437 participants, above the 162-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (170% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02547233, a Phase 3 study of Actinic Keratosis, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 437 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment.
Primary Outcome
Complete clearance was defined as an AK count of zero, i.e. no clinically visible AKs (actinic keratosis lesions) in the treatment area. The table shows the percentage of mean number of subjects across imputations with complete clearance.
Conditions Studied
Interventions
- DRUG Vehicle gel
- DRUG LEO 43204 gel
Study Locations (1)
Illinois
- Altman Dermatology Associates - Arlington Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
What the finished NCT02547233 record still lists
NCT02547233 is an interventional study that assigns participants to a tested intervention. The registered 437 participants enrollment target is mid-sized for trials with a published cap, above the 162-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (170% higher).
The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle gel is the first listed.
NCT02547233 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02547233 about?
NCT02547233 is a clinical study titled "Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up". The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment.
What is the current status of trial NCT02547233?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2015-11. Estimated completion is 2017-11.
What conditions does trial NCT02547233 study?
This clinical trial studies the following conditions: Actinic Keratosis.
What interventions are being tested in trial NCT02547233?
The interventions under investigation include: Vehicle gel (DRUG), LEO 43204 gel (DRUG).
Who is sponsoring clinical trial NCT02547233?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02547233 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02547233's enrollment target sits among peer trials
437 3rd of 16 higher than 14 of 16 other Actinic Keratosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Actinic Keratosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
ACTIVE NOT RECRUITING · Phase 3
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
ACTIVE NOT RECRUITING · Phase 3
-
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
COMPLETED · Phase 3
-
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
COMPLETED · Phase 3
-
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
COMPLETED · Phase 3
-
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia